FACILITATE

Almirall joins FACILITATE, a patient-focused Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants

Almirall joins FACILITATE, a patient-focused Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants

Almirall brings experience in privacy and pharmaceutical law, as well as in developing guidance, standards and recommendations for communicating clinical trial data to patients The project will last four years and will involve 27 partners from 16 EU and extra-EU Member States, including patient organisations, hospitals, universities, SMEs and members of the European Federation of …

Almirall joins FACILITATE, a patient-focused Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants Read More »

Almirall joins FACILITATE, a patient-focused Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants

Almirall joins FACILITATE, a patient-focused Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants

Barcelona, ​​Spain–(BUSINESS WIRE)–Almirall, SA (ALM)a global biopharmaceutical company focused on skin health, today announced its participation in FACILITATE(FrAwork for VSIINicholasL trIon the day of the participantsBY reuse for full use Jtransparent and Eethical ecosystem) a patient-focused project of the Innovative Medicines Initiative (IMI) aimed at create a framework for access and reuse of clinical trial …

Almirall joins FACILITATE, a patient-focused Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants Read More »